pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,786 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1775Endpoints1385Fierce Biotech702BioSpace695BioPharma Dive523raps231onclive165fda recalls
therapy area
allOncology12299Rare Disease3191Immunology2860Cardiology2726Hematology2173Pulmonology2138Vaccines
  • Allen Institute launches multi-hundred-million-dollar effort to turn brain atlas data into neurodegenerative drug candidates
    The Allen Institute, a Seattle nonprofit known for basic brain research, announced a major new effort to move its brain‑atlas knowledge toward drug development. The program will invest several hun…
    Endpoints · 5mo agoPositive↗ source
  • FDA issues draft guidance outlining data flexibilities for cell and gene therapy developers
    The FDA released a draft guidance from its Center for Biologics Evaluation and Research (CBER) that clarifies how developers of cell and gene therapies can use existing data and prior knowledge in…
    Endpoints · 5mo agoRegulatoryNeutral↗ source
← prev
page 62 of 72
next →
111
fda medwatch111
globenewswire health73
fda press59
1794
Psychiatry & CNS1204
Ophthalmology1050
Endocrinology & Metabolism775
Pain775
Nephrology759
  • NewLimit secures $435M funding, valuation tops $3B, aims for human trials in 2027
    NewLimit, a Bay Area anti-aging biotech, announced a financing round that raised $435 million, valuing the company at more than $3 billion. The round is among the largest private biotech financing…
    Endpoints · 5mo agoDealPositive↗ source
  • Contraline secures $92.5M Series B to fund Phase 3 trial of male contraceptive gel
    Contraline, a startup developing a male contraceptive, announced it has closed a Series B financing round worth $92.5 million. The capital will be used to advance its candidate, referred to as NES…
    Endpoints · 5mo agoDealPositive↗ source
  • Travere Therapeutics pays $112 million upfront to China’s Everest Medicines to expand rare kidney disease pipeline
    Travere Therapeutics, a San Diego‑based biotech, announced a partnership with China‑based Everest Medicines to strengthen its rare kidney disease portfolio beyond its approved drug Filspari. Under…
    Endpoints · 5mo agoDealPositive↗ source
  • Legend Biotech reports first in vivo CAR-T data from Chinese lymphoma trial
    Legend Biotech has released its first in vivo CAR-T cell therapy data, marking the next step after its CAR-T product Carvykti. The data come from an investigator-initiated trial in China that enro…
    Endpoints · 5mo agoPositive readoutPositive↗ source
  • Celcuity reports combo regimen with gedatolisib doubles progression‑free survival odds in late‑stage breast cancer
    Celcuity announced at ASCO 2026 that its experimental drug gedatolisib, used in a combination regimen, showed a significant improvement in a late‑stage breast cancer trial. The data revealed that…
    Endpoints · 5mo agoPositive readoutPositive↗ source
  • Michigan lawmakers introduce bipartisan bill to curb China-U.S. biotech partnerships
    A bipartisan group of Michigan legislators has unveiled a new bill aimed at limiting cross-border transactions between Chinese and American biotechnology firms. The proposal, introduced by Rep. Jo…
    Endpoints · 5mo agoRegulatoryNegative↗ source
  • Abivax’s ulcerative colitis Phase 3 trial shows promising efficacy but cancer cases raise safety concerns
    Abivax announced that its Phase 3 maintenance trial in ulcerative colitis produced results it called “landmark,” showing the drug’s ability to keep patients in remission. The company emphasized th…
    Endpoints · 5mo agoNegative readoutNegative↗ source
  • Praxis Precision Medicines reports late-stage failure of seizure drug and pauses second trial
    Praxis Precision Medicines had enjoyed a period of momentum, reporting two notable clinical successes in the past eight months. The company’s pipeline had been viewed positively by investors and an…
    Endpoints · 5mo agoNegative readoutNegative↗ source
  • Eli Lilly gives hospitals five days to meet new 340B claims data policy or lose discounts
    Eli Lilly has told a group of hospitals they must adhere to a new claims data policy within five days or their participation in the 340B drug discount program will be terminated. The policy requir…
    Endpoints · 5mo agoRegulatoryNegative↗ source
  • ASCO 2026 hints at future role for VEGF-targeted cancer drugs as complement to immunotherapy
    At the recent ASCO meeting, experts discussed the outlook for VEGF-targeted therapies in oncology. Earlier hopes that this new class could match the blockbuster success of pembrolizumab (Keytruda)…
    Endpoints · 5mo agoNeutral↗ source
  • Fulcrum Therapeutics abandons its only sickle cell drug after FDA cites concerns linked to withdrawn cancer therapy
    Fulcrum Therapeutics announced it is ending development of its sole clinical‑stage sickle cell medicine. The move follows feedback from the U.S. Food and Drug Administration that referenced a rece…
    Endpoints · 5mo agoRegulatoryNegative↗ source
  • Obesity care startup Ilant Health secures $15M Series A funding
    Ilant Health, a startup focused on obesity care, announced a $15 million Series A financing round. The capital will be used to broaden its personalized treatment platform, which leverages virtual…
    Endpoints · 5mo agoDealPositive↗ source
  • Eli Lilly's $7B acquisition of Kelonia highlighted by full-cohort response in in-vivo CAR-T trial for multiple myeloma
    At ASCO 2026, Kelonia Therapeutics presented data on its in-vivo CAR-T platform for multiple myeloma. The report covered 18 patients treated with the therapy, all of whom showed encouraging outcom…
    Endpoints · 5mo agoDealPositive↗ source
  • Servier acquires Edgewise's muscular dystrophy assets for $1.55 billion
    Servier announced it will purchase the muscular dystrophy business from Edgewise Therapeutics. The deal involves an upfront payment of $1.55 billion, giving the French company rights to Edgewise's…
    Endpoints · 5mo agoDealPositive↗ source
  • AstraZeneca reports promising triplet therapy results in liver cancer subgroup
    AstraZeneca presented new data at ASCO 2026 showing that a regimen combining a targeted agent with two immunotherapies produced clinical benefit in a subset of liver cancer patients. The study eva…
    Endpoints · 5mo agoPositive readoutPositive↗ source
  • Priority review voucher prices have doubled over three years, likely to remain high
    Recent reporting highlights that the price of FDA priority review vouchers has roughly doubled from three years ago. The vouchers provide a shortcut that can shave about four months off the agency…
    Endpoints · 5mo agoRegulatoryNeutral↗ source
  • CRISPR-based epigenetic editing shows promise in silencing hepatitis B genes
    A new CRISPR-based technique targets the epigenome to turn off genes that drive chronic hepatitis B infection, doing so without changing the underlying DNA sequence. Tune Therapeutics reported ear…
    Endpoints · 5mo agoPositive readoutPositive↗ source
  • Shionogi receives FDA nod for first oral COVID-19 post-exposure prevention pill
    Shionogi announced that the U.S. Food and Drug Administration has granted approval for its oral antiviral designed to prevent COVID-19 after exposure. The product is indicated for adults and child…
    Endpoints · 5mo agoApprovalPositive↗ source
  • Agios pays $25 million for global rights to Oscotec’s SYK inhibitor cevidoplenib
    Agios Therapeutics announced it has secured an exclusive worldwide license for Oscotec’s experimental SYK inhibitor, cevidoplenib. Under the agreement, Agios will pay $25 million up front to Oscot…
    Endpoints · 5mo agoDealNeutral↗ source
  • Avenzo Therapeutics to go public via reverse merger with Rallybio after Candid partnership ends
    On June 1, 2026, Avenzo Therapeutics announced that it will become a publicly traded company through a reverse merger with Rallybio, securing a Nasdaq listing after its previous partner, Candid, en…
    Endpoints · 5mo agoDealPositive↗ source
  • Turn Therapeutics reports faster symptom relief in Phase 2 eczema trial
    Turn Therapeutics, a California biotech, disclosed interim results from its Phase 2 study of a topical treatment for atopic dermatitis. The analysis of 50 patients indicated that skin symptoms imp…
    Endpoints · 5mo agoPositive readoutPositive↗ source
  • J&J’s Erleada reduces metastasis or death risk by 20% in early‑stage prostate cancer study
    Johnson & Johnson presented data on its hormone therapy drug Erleada at the ASCO 2026 meeting. The study focused on men with early‑stage prostate cancer who received the drug around the time of sur…
    Endpoints · 5mo agoPositive readoutPositive↗ source
  • Oculis’ investigational eye drop OCS-01 fails Phase 3 trials for diabetic macular edema, shares tumble
    Oculis announced that its experimental eye drop OCS-01 did not meet primary endpoints in two Phase 3 studies aimed at treating diabetic macular edema. The trials were intended to evaluate the drug…
    Endpoints · 5mo agoNegative readoutNegative↗ source